Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

AvroBio, Inc.. (9/26/17). "Press Release: AvroBio, Inc. Appoints Katina Dorton as Chief Financial Officer". Cambridge, MA.

Organisations Organisation AvroBio Inc. (Nasdaq: AVRO)
  Group AvroBio (Group)
  Organisation 2 Immatics Biotechnologies GmbH
  Group Immatics (Group)
Products Product gene therapy
  Product 2 investment banking
Persons Person Dorton, Katina (AvroBio 201709– CFO before Immatics + Needham & Co + Morgan Stanley + Sullivan & Chromwell)
  Person 2 MacKay, Geoff (AvroBio 201703 CEO)

AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announces today the appointment of Katina Dorton as Chief Financial Officer.

“I am delighted to welcome Katina to the AVROBIO team,” said Geoff MacKay, AVROBIO’s President and Chief Executive Officer. “Katina comes to us with extensive experience in biotechnology, capital markets and strategic corporate transactions. I am confident that she will be of great value to AVROBIO as we continue to grow and develop our gene therapy programs.”

“AVROBIO is an exciting, innovative gene therapy company with tremendous potential,” added Ms. Dorton. “I share its commitment to become a leading gene therapy company and bringing forward important therapies for the patients we are serving. I look forward to working with the remarkable team at AVROBIO and the strong existing investor base.”

Ms. Dorton brings more than 20 years of investment banking experience and has served as a senior strategic and financing advisor to numerous companies in the life sciences and biotechnology sectors. Prior to joining AVROBIO, Ms. Dorton served as Chief Financial Officer of Immatics GmbH. She is a former Managing Director, Morgan Stanley in New York and Frankfurt, Germany, serving 12 years at the firm. Prior to her investment banking career Ms. Dorton was an attorney in private practice with Sullivan & Cromwell. Ms. Dorton holds a J.D. from the University of Virginia School of Law, an M.B.A. from George Washington University and a B.A. from Duke University.

About AVROBIO, Inc.

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its Phase 1 program in Fabry disease and pre-Phase 1/2 program in Gaucher disease, while actively building a pipeline of therapies to treat Pompe disease and other rare and non-rare genetic diseases. AVROBIO also has an immuno-oncology gene therapy program. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit

Media Inquiries:

Kirsten Dupuis

Record changed: 2019-11-03


Picture [iito] Männer Ballett 650x80px

More documents for AvroBio (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

» top